(Q36326443)

13 August 2017

1 reference

title

DNA vaccines for therapy of tuberculosis: where are we now? (English)

1 reference

13 August 2017

0 references

Douglas B Lowrie

1

1 reference

PubMed ID

16316711

13 August 2017

language of work or name

English

0 references

publication date

16 November 2005

1 reference

13 August 2017

1 reference

13 August 2017

24

1 reference

13 August 2017

12

1 reference

13 August 2017

1983-1989

1 reference

Towards a DNA vaccine against tuberculosis.

13 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

A DNA prime-Mycobacterium bovis BCG boost vaccination strategy for cattle induces protection against bovine tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

A DNA prime-live vaccine boost strategy in mice can augment IFN-gamma responses to mycobacterial antigens but does not increase the protective efficacy of two attenuated strains of Mycobacterium bovis against bovine tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Improved immunogenicity of DNA vaccination with mycobacterial HSP65 against bovine tuberculosis by protein boosting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Prime-boost vaccination based on DNA and protein-loaded microspheres for tuberculosis prevention.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Technical and regulatory hurdles for DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Identification and characterization of murine cytotoxic T cells that kill Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Therapy of tuberculosis in mice by DNA vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Pulmonary necrosis resulting from DNA vaccination against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Factors associated with severe granulomatous pneumonia in Mycobacterium tuberculosis-infected mice vaccinated therapeutically with hsp65 DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Immunotherapy with plasmid DNA encoding mycobacterial hsp65 in association with chemotherapy is a more rapid and efficient form of treatment for tuberculosis in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Immune responses to tuberculosis in developing countries: implications for new vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

IL-4 in tuberculosis: implications for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Quantitative differences in interleukin-2 and interleukin-4 production by antigen-stimulated splenocytes from individually- and group-housed mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Animal models. Can a mouse be standardized?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

DNA immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Protective effect of DNA vaccine during chemotherapy on reactivation and reinfection of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Enhancement of immunocompetence in tuberculosis by DNA vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Patients with active tuberculosis often have different strains in the same sputum specimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Superinfecting mycobacteria home to established tuberculous granulomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Therapeutic effects of Ag85B and MPT64 DNA vaccines in a murine model of Mycobacterium tuberculosis infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Immune regulatory effect of pHSP65 DNA therapy in pulmonary tuberculosis: activation of CD8+ cells, interferon-gamma recovery and reduction of lung injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

The role of Toll-like receptors in combating mycobacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Influence of trehalose 6,6'-dimycolate (TDM) during mycobacterial infection of bone marrow macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Innate inhibition of adaptive immunity: Mycobacterium tuberculosis-induced IL-6 inhibits macrophage responses to IFN-gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Mycobacterial lipoarabinomannans modulate cytokine production in human T helper cells by interfering with raft/microdomain signalling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Toll-like receptor 2 (TLR2)-dependent-positive and TLR2-independent-negative regulation of proinflammatory cytokines by mycobacterial lipomannans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Mycobacterium tuberculosis inhibits macrophage responses to IFN-gamma through myeloid differentiation factor 88-dependent and -independent mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Vaccination of guinea pigs with DNA encoding the mycobacterial antigen MPB83 influences pulmonary pathology but not hematogenous spread following aerogenic infection with Mycobacterium bovis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Adjunctive immunotherapy of mycobacterial infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Creating space: an antigen-independent, CpG-induced peripheral expansion of naive and memory T lymphocytes in a full T-cell compartment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Immunostimulatory bacterial DNA sequences activate dendritic cells and promote priming and differentiation of CD8+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

A role for Toll-like receptor 4 in dendritic cell activation and cytolytic CD8+ T cell differentiation in response to a recombinant heat shock fusion protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Mycobacterial heat shock protein 65 enhances antigen cross-presentation in dendritic cells independent of Toll-like receptor 4 signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Multiple intracellular routes in the cross-presentation of a soluble protein by murine dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

The heat-shock protein receptors: some answers and more questions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th1-boosting?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Heat-shock proteins induce T-cell regulation of chronic inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Inhibition of adjuvant-induced arthritis by DNA vaccination with the 70-kd or the 90-kd human heat-shock protein: immune cross-regulation with the 60-kd heat-shock protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

DNA Fragments of the Human 60-kDa Heat Shock Protein (HSP60) Vaccinate Against Adjuvant Arthritis: Identification of a Regulatory HSP60 Peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

Real world TB vaccines: clinical trials in TB-endemic regions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.010

10.1016/J.VACCINE.2005.11.010

7 January 2021

Identifiers

DOI

1 reference

13 August 2017

1 reference

PubMed ID

16316711